Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Royal jelly + panthenol (marketed under the brand name Pedyphar) is a topical combination therapy developed by European Egyptian Pharmaceutical Industries for the treatment of diabetic foot ulcers. Royal jelly is a complex biological substance secreted by honey bees that contains bioactive proteins (Major Royal Jelly Proteins) and fatty acids (such as 10-hydroxy-2-decenoic acid) which exhibit antimicrobial, anti-inflammatory, and regenerative properties. These components stimulate fibroblast migration and collagen synthesis, essential for wound closure. Panthenol, a provitamin of B5, acts as a humectant and is converted in the skin to pantothenic acid, a precursor of coenzyme A. This metabolic pathway supports epithelialization and the maintenance of the skin barrier. The combination is formulated as an ointment to provide a protective environment that accelerates the healing of chronic diabetic wounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on royal jelly + panthenol.